Clinical Trials

 

Somatostatin (Octreotide®, Lanreotide® is biochemically related drug) is a naturally occurring hormone in humans that binds to a receptor protein on the surface of renal cells  and blocks cAMP (an intracellular second messenger) formation inside the cell.  Fluid secretion and cell proliferation are both reduced resulting in decreased cyst and kidney size.

 

---

 

Somatostatin Clinical Trials

 

Somatostatin in Polycystic Kidney: A Long-term Three Year Follow-up Study   Intervention: Drug - Long-acting somatostatin Sponsor: Mario Negri Institute for Pharmacological Research Study Phase: III Status: Recruiting Age Group: 18-75 Enrollment goal: 66 Description: To compare the effects on disease progression of a three year treatment regimen using long-acting somatostatin or placebo in patients with ADPKD and normal renal function or mild to moderate renal insufficiency. Contact: Norberto Perico, MD at 0039 035-45351 or perico@marionegri.it Website: NIH Study Details

 

Octreotide in Severe Polycystic Liver Disease   Intervention: Drug - Octreotide (long-acting somatostatin) Sponsor: Mayo Clinic; Novartis Study Phase: II & III Status: Recruiting Age Group: 18-80 Enrollment goal: 42 Description: To evaluate the effect of Octreotide LAR on liver volumes of patients with severe polycystic liver disease who are not candidates for or decline surgical treatments such as liver cyst fenestration or liver transplantation. Contact: Marie Hogan, M.D., Ph.D. at 507-538-9851 or Linda Page at 507-538-9851 Website: NIH Study Details

 

Lanreotide as Treatment of Polycystic Liver Disease   Intervention: Lanreotide Sponsor: Radboud University Study Phase: II & III Status: Completed Age Group: 18-88 Enrollment goal: 38 Description: To assess the effectiveness of lanreotide in controlling total liver volume in patients with polycystic livers. Contact: info@livercyst.org Website: NIH Study Details